IMAB I-Mab Stock Quote

IMAB [NASD]

Index	-	P/E	-	EPS (ttm)	-4.58	Insider Own	1.07%	Shs Outstand	78.52M	Perf Week	2.82%
Market Cap	949.35M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	0.00%	Shs Float	37.92M	Perf Month	36.93%
Income	-348.10M	PEG	-	EPS next Q	-	Inst Own	58.10%	Short Float	8.04%	Perf Quarter	-36.63%
Sales	13.10M	P/S	72.47	EPS this Y	-545.60%	Inst Trans	-0.75%	Short Ratio	2.42	Perf Half Y	-75.11%
Book/sh	8.67	P/B	1.35	EPS next Y	-	ROA	-41.70%	Target Price	76.67	Perf Year	-84.32%
Cash/sh	7.86	P/C	1.49	EPS next 5Y	26.00%	ROE	-48.10%	52W Range	8.05 - 81.47	Perf YTD	-75.35%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-45.40%	52W High	-85.66%	Beta	-
Dividend %	-	Quick Ratio	7.60	Sales past 5Y	-	Gross Margin	47.30%	52W Low	45.09%	ATR	1.00
Employees	378	Current Ratio	7.70	Sales Q/Q	-97.70%	Oper. Margin	-	RSI (14)	53.54	Volatility	8.62% 9.06%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-45.30%	Profit Margin	-	Rel Volume	0.36	Prev Close	12.34
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.26M	Price	11.68
Recom	1.60	SMA20	9.34%	SMA50	4.74%	SMA200	-66.23%	Volume	453,771	Change	-5.35%

Dec-09-21

Initiated

Siebert Williams Shank

Buy

$96

Jun-02-21

Initiated

Daiwa Securities

Buy

Mar-15-21

Initiated

Needham

Buy

$75

Mar-03-21

Reiterated

H.C. Wainwright

Buy

$55 → $75

Feb-25-21

Initiated

Piper Sandler

Overweight

$75

Dec-07-20

Initiated

H.C. Wainwright

Buy

$55

Jul-27-20

Initiated

Cantor Fitzgerald

Overweight

$50

Feb-12-20

Initiated

China Renaissance

Buy

Feb-11-20

Initiated

Jefferies

Buy

$16

Jul-06-22 08:00AM	I-Mab to Host 2022 R&D Day PR Newswire -5.35%
Jun-23-22 08:00AM	I-Mab Receives Top Rankings in Five Categories by Institutional Investor PR Newswire
Jun-15-22 08:30AM	I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 PR Newswire +8.06%
May-31-22 08:00AM	I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency PR Newswire +5.20%
May-26-22 05:01PM	I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab PR Newswire +6.40%
May-19-22 08:00AM	I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab PR Newswire
May-12-22 06:16AM	We're Hopeful That I-Mab (NASDAQ:IMAB) Will Use Its Cash Wisely Simply Wall St.
May-05-22 08:00AM	I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act PR Newswire -5.96%
Apr-28-22 04:01PM	I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer PR Newswire
Apr-20-22 08:25PM	Chinese Biotech I-Mab Weighing Options Including Sale Bloomberg +12.85%
Mar-31-22 08:00AM	I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment PR Newswire -14.30%
Mar-29-22 06:10AM	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 PR Newswire +15.07%
Mar-25-22 08:00PM	Hong Kong SPAC Rush Attracts Olympic Champions to Sofa Moguls Bloomberg -11.05%
Mar-18-22 08:00AM	I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022 PR Newswire +17.31%
Mar-15-22 02:22PM	Further weakness as I-Mab (NASDAQ:IMAB) drops 40% this week, taking one-year losses to 76% Simply Wall St. +7.50%
08:00AM	I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act PR Newswire
Mar-09-22 08:00AM	I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting PR Newswire +7.29%
Mar-03-22 08:00AM	I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer PR Newswire -11.29%
Mar-01-22 09:28AM	Billionaire Ray Dalios Top 10 Small-Cap Stock Picks Insider Monkey +6.63%
Feb-26-22 12:58PM	Campbell Wilsons Old Well Partners Is Buying These 10 Stocks Insider Monkey
Feb-08-22 09:38AM	Strategic Vision Investment Ltd Buys Amazon. ... GuruFocus.com -5.01%
Jan-28-22 08:00AM	I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs PR Newswire +6.75%
Jan-27-22 01:38PM	Dorsey Wright & Associates Buys Coterra Energy Inc, Fortinet Inc, Icon PLC, Sells RH, ... GuruFocus.com -15.25%
Jan-18-22 08:00AM	I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors PR Newswire
Jan-14-22 08:00AM	I-Mab Announces Execution of Senior Management Team Share Purchase Plan PR Newswire
Jan-12-22 08:00AM	I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors PR Newswire
Jan-06-22 08:00AM	I-Mab Announces Senior Management Team Share Purchase Plan PR Newswire
Jan-04-22 09:32AM	I-Mab (IMAB) Sees Hammer Chart Pattern: Time to Buy? Zacks -7.76%
Dec-27-21 08:00AM	I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors PR Newswire
Dec-20-21 08:00AM	I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization PR Newswire
Dec-15-21 08:00AM	I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China PR Newswire
Dec-14-21 06:00AM	I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021 PR Newswire
Dec-09-21 08:00AM	I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma PR Newswire
Dec-08-21 08:00AM	I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease PR Newswire
Dec-07-21 10:26AM	Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug Zacks
08:00AM	I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited PR Newswire
Dec-03-21 08:00AM	I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors PR Newswire -8.15%
Nov-15-21 11:00AM	Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing Zacks
Nov-13-21 08:41AM	Top 10 Stock Picks of Philip Bests Quaero Capital Insider Monkey
Nov-10-21 08:19AM	The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga
07:20AM	I-Mab Shares Gain On Licensing Pact For Its Human Growth Hormone In China Benzinga
04:30AM	I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa PR Newswire
Nov-09-21 08:05AM	I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC PR Newswire
Nov-08-21 08:30AM	DayDayCook Adds New Independent Directors and New Advisory Board Member GlobeNewswire
08:00AM	I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE PR Newswire
08:00AM	DDC Enterprise Limited and Ace Global Business Acquisition Limited Announce Initial Filing of Preliminary Proxy Statement in Connection with Proposed Business Combination and the Appointment of Independent Directors and Advisor GlobeNewswire
Nov-04-21 09:00AM	I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021 PR Newswire
Nov-03-21 08:00AM	I-Mab Announces Upcoming Participation at November Conferences PR Newswire
Nov-01-21 08:00AM	I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments PR Newswire
Oct-26-21 08:00AM	I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China PR Newswire -6.12%
Oct-22-21 08:00AM	I-Mab Expands U.S. Footprint with New R&D Site in San Diego PR Newswire
Oct-18-21 08:00AM	I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China PR Newswire
Oct-13-21 08:00AM	I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China PR Newswire
Oct-05-21 08:00AM	I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting PR Newswire
Oct-01-21 08:00AM	I-Mab Announces Upcoming Participation at October Conferences PR Newswire
Sep-30-21 08:00AM	I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab PR Newswire
Sep-28-21 08:27AM	I-Mab Weighing Partnership, Stake Sale to Pharma Giants Bloomberg
08:00AM	I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors PR Newswire
Sep-20-21 12:13PM	I-Mab Stock Joins Rank Of Stocks With RS Ratings Over 90 Investor's Business Daily
Sep-13-21 08:03AM	I-Mab (NASDAQ:IMAB) delivers shareholders favorable 92% return over 1 year, surging 14% in the last week alone Simply Wall St.
08:00AM	I-Mab Added to FTSE ESG Index Series PR Newswire
Sep-02-21 08:00AM	I-Mab Added to FTSE Russell Global Equity Index Series PR Newswire
Sep-01-21 12:53PM	I-Mab Stock Flashes Vital Signs With 89 RS Rating Investor's Business Daily
Aug-31-21 04:30PM	I-MAB (IMAB) Q2 2021 Earnings Call Transcript Motley Fool +10.50%
06:00AM	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021 PR Newswire
Aug-30-21 08:00AM	I-Mab Announces Upcoming Participation at September Conferences PR Newswire
Aug-27-21 11:51AM	Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa Zacks
Aug-19-21 07:00AM	I-Mab Announces Establishment of Environmental, Social and Governance Committee PR Newswire -15.79%
Aug-17-21 08:00AM	I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021 PR Newswire -5.96%
Aug-11-21 08:00AM	I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19 PR Newswire -8.59%
Jul-30-21 08:00AM	I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease PR Newswire
Jul-29-21 08:00AM	I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million PR Newswire
Jul-28-21 07:15AM	I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China PR Newswire +21.52%
01:04AM	Chinese Drug Developer I-Mab Proceeds With Shanghai Dual Listing Bloomberg
Jul-27-21 08:35AM	I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange PR Newswire
Jul-21-21 04:53AM	Hedge Funds Have Never Been This Bullish On I-Mab (IMAB) Insider Monkey
Jul-09-21 08:00AM	I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms PR Newswire +7.69%
Jul-01-21 12:59PM	10 Best Stocks to Buy According to DiDi (NYSE: DIDI)s Early Investor Billionaire Zhang Lei Insider Monkey
08:00AM	I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio PR Newswire
Jun-30-21 08:00AM	I-Mab Honored with Top Rankings by Institutional Investor PR Newswire
Jun-29-21 08:00AM	I-Mab Announces Upcoming Participation at July Conference PR Newswire
Jun-25-21 08:00AM	I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus PR Newswire
Jun-21-21 08:00AM	I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board PR Newswire +5.22%
Jun-14-21 01:41PM	I-Mab Seeks Multibillion-Dollar Cancer Drug Partnership Bloomberg
Jun-08-21 04:36AM	Calculating The Fair Value Of I-Mab (NASDAQ:IMAB) Simply Wall St.
Jun-02-21 08:00AM	I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab PR Newswire
Jun-01-21 08:00AM	I-Mab Appoints Ruyi He and Rong Shao to Board of Directors PR Newswire
May-27-21 08:00AM	I-Mab Announces Upcoming Participation at June Conferences PR Newswire +9.16%
May-20-21 06:17AM	I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings Benzinga +14.17%
May-19-21 06:00PM	I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 PR Newswire
06:30AM	ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors GlobeNewswire
May-18-21 08:00AM	I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome PR Newswire
May-14-21 07:00AM	ProMIS Neurosciences Announces First Quarter 2021 Results GlobeNewswire
May-13-21 08:00AM	I-Mab Added to MSCI China Index PR Newswire
Apr-29-21 08:00AM	I-Mab Announces Upcoming Participation at May Conferences PR Newswire
Apr-28-21 08:00AM	I-Mab Filed 2020 Annual Report on Form 20-F PR Newswire -6.89%
Apr-26-21 09:58AM	I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study Benzinga
07:00AM	I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis PR Newswire
Apr-14-21 08:30AM	I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting GlobeNewswire +11.00%
Apr-06-21 08:00AM	I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors GlobeNewswire

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience